The FDA needs to set standards for using artificial intelligence in drug development
November 7, 2019
Author
Charles K. Fisher
for STAT News
Published
November 7, 2019
Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.
Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials
April 20, 2020
“Unlearn’s pioneering use of Digital Twins will limit the number of patients that need to go on placebo while also reducing overall trial enrollment time."
A fascinating approach to the problem of how to make clinical trials more efficient, and understand more about what may be possible with more and better patient data.
